In this online, self-learning activity:
Pyruvate kinase (PK) is an enzyme that plays a major role in a metabolic pathway integral to the production of ATP, and a deficiency in the enzyme (PKD) is one of the most common enzyme-related glycolytic defects in a pathway integral to the production of ATP. It is transmitted as an autosomal recessive trait and is caused by mutations in the PKLR gene on chromosome 1, and over one hundred eighty of these mutations have been associated with PKD. While PKD affects approximately five people of European descent per 100,000 (data in other patient populations are lacking), it is one of the more frequent causes of chronic hemolysis. Anemia arising from the condition may range from mild and fully compensated to life-threatening in severity.
Healthcare professionals specializing in: hematology; nurse practitioners, physician assistants, and pharmacists who specialize in hematology; and those who otherwise commonly care for or clinically encounter patients with PKD.
Commercial Support Disclosure: This program is supported by an educational grant from Agios.
This activity is free of charge.
Release Date: May 12, 2022 -- Expiration Date: May 12, 2024
Faculty: Sujit Sheth , MD
Faculty introduction, disclosures |
PKD introductory content
· PK-specific testing · Chronic hemolysis-related complications and iron overload · Barriers to diagnosis |
Treatment of PKD
· Transfusions · Phototherapy, · Folic acid · Splenectomy
· Allogeneic stem cell transplant · CRISPR-mediated correction of PKLR mutation · RBC PK activator therapy
|
Conclusions and best practice recap |
By the end of the session the participant will be able to:
ACCME Activity #202290869
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Faculty Disclosure:
Sujit Sheth , M.D., has received financial compensation for consulting and/or research work from: Agios, BMS, Celgene, Acceleron, Chiesi, Bluebird bio, Vertex, Imara, Forma, Dispersol, and Phoenicia Bio.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty will discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Agios.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.